About Nanolattix

Nanolattix Group is a national high-tech enterprise integrating R&D, technology transfer, production, and sales, established in Shanxi by Dr. Zhican Qu - a high-level overseas life sciences talent introduced through state programs - who led the core international technical team to found the company with proprietary biotechnologies and startup capital in response to Shanxi Province's economic transformation initiative. Focusing on life and health, NanoLattix specializes in innovation and technology commercialization across medical pharmaceuticals and general wellness, covering biomedicine, medical devices, plant extraction, and precision health industries. To date, Dr. Qu's team has filed over 50 biomedical invention patents, maintaining multi-level innovation, rapid scientific achievement translation, and self-sustained progressive development.

2016 Year

Date of Establishment

50 Remainder

Authorized patent

Learn more +

Nanolattix Biotechnology

Nanolattix Biotechnology has established the Bio-Lattix core biotechnology platform, covering three modules: drug target screening, antibody engineering, and ADC patented drug research. The company has built over 10 new drug development pipelines, including monoclonal antibody ADC, bispecific antibody ADC, and nanobody ADC, and has deployed 7 RDC innovative drug pipelines for precision internal radiotherapy combining antibodies and radioisotopes. The core product, T320 anticancer drug, targets multiple solid tumors such as cervical cancer, pancreatic cancer, and non-small cell lung cancer. The drug has received ODD (Orphan Drug Designation) from the US FDA for pancreatic cancer and will fill the gap in novel target biomedicine in China. It aims for market approval within two to three years, with an estimated market potential exceeding RMB 10 billion.

Nanolattix Health

Moving forward, Nanolattix embraces biotechnology as its mission to advance human health, striving to become a globally recognized pharmaceutical and healthcare industry group.

Learn more +